Laboratorios Farmaceuticos Rovi, S.A./ADR

Drug Name	Phase	Indication	Designations	Patent
Fixed Dose Etoricoxib + Betamethasone	Phase 3	Bursitis	-	-
Depigoid Parietaria judaica 1000DPP/ml	Phase 3	Allergic Rhinoconjunctivitis	-	-
Glucosamine and chondroitin sulfate combination (Eurofarma)	Phase 3	Osteoarthritis of Knee	-	-
Minoxidil Topical Foam	Phase 3	Alopecia	-	-
Study group - quadrivalent recombinant hemagglutinin influenza vaccine	Phase 3	Influenza, Human	-	-
Metformin Glycinate	Phase 3	Severe Acute Respiratory Syndrome Coronavirus 2	-	-
Allergen extract (Phleum pratense)	Phase 3	Seasonal Allergic Rhinitis	-	-
Rizatriptan 10 mg + Naproxen 550mg	Phase 3	Migraine	-	-
Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg	Phase 3	Asthma Copd	-	-
Nimotuzumab	Phase 3	Esophageal Cancer	-	-
Fixed combination of budesonide and formoterol	Phase 3	Asthma	-	-
Filgrastim (Eurofarma)	Phase 3	Neutropenia in Breast Cancer	-	-
DMMET-01	Phase 3	Diabetes Type 2	-	-
Celecoxib + Acetaminohen	Phase 3	Joint Pain	-	-
Dexketoprofen/Vitamin B	Phase 3	Acute Low Back Pain	-	-
Lactase	Phase 3	Hypolactasia	-	-
Foraseq	Phase 3	ASTHMA	-	-
FDC of codeine 30 mg/dipyrone 500 mg	Phase 3	Pain	-	-
Immunotherapy with modified extract of O. europaea pollen	Phase 3	Allergy	-	-
Etoricoxib + Cyanocobalamin fixed dose	Phase 3	Acute Low-back Pain	-	-
Desloratadine / Betamethasone in fixed dose	Phase 3	Allergic Rhinitis	-	-
Mometasone furoate	Phase 3	Mild to Moderate Persistent Allergic Rhinitis	-	-
FDC of oxycodone 5 mg/ibuprofen 400 mg	Phase 3	Pain	-	-
Noex	Phase 3	Allergic Rhinitis	-	-
Metformin hydrochloride	Phase 3	Type 2 Diabetes	-	-
Desloratadine , Prednisolone	Phase 3	Allergic Rhinitis	-	-
Chlorthalidone 25 mg + amiloride hydrochloride 5 mg	Phase 3	Arterial Hypertension	-	-
Losartan/Chlorthalidone in fixed dose	Phase 3	Essential Arterial Hypertension	-	-
Etoricoxib + Tizanidine fixed dose	Phase 3	Acute Low-back Pain	-	-
Levetiracetam	Phase 3	Epilepsy	-	-
Candicort®	Phase 3	Tinea	-	-
Glucosamine sulphate and chondroitin sulphate association	Phase 3	Osteoarthritis of the Knee	-	-
Group 1	Phase 3	Nasal Congestion and Inflammations	-	-
A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)	Phase 3	Type 2 Diabetes	-	-
Etoricoxib 90 mg / Tramadol 50 mg	Phase 3	Acute Low Back Pain	-	-
Sodium picosulphate, light magnesium oxide and anhydride citric acid.	Phase 3	Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.	-	-
Celecoxib+Pregabalin+Vitamin B fixed dose	Phase 3	Chronic Low-back Pain	-	-
Immunotherapy with modified extract of Olea europaea pollen	Phase 3	Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen	-	-
glucosamine sulfate /chondroitin sulfate - capsules	Phase 3	Knee Osteoarthritis	-	-
Difluprednate 0.05%	Phase 3	Cataract	-	-
Lactase Oral Tablets	Phase 3	Lactose Intolerance	-	-
Lucentis®	Phase 3	Diabetic Macular Edema	-	-
Liquaemin	Phase 3	Hemodialysis Complication	-	-
Alleance®	Phase 3	Myopia	-	-
application of the topic gel	Phase 3	Acne Vulgaris	-	-
Salmeterol/Fluticasone	Phase 3	Asthma	-	-
Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.	Phase 3	Hypercholesterolemia	-	-
Dextralgen	Phase 3	Lumbar Sciatic Pain	-	-
Etoricoxib + Betamethasone fixed dose	Phase 3	Gout Arthritis	-	-
Inj. Goserelin (Test) Subcutaneously	Phase 3	Advanced Prostate Cancer	-	-
brompheniramine + phenylephrine	Phase 3	Nasal Congestion and Inflammations	-	-
Eszopiclone	Phase 3	INSOMNIA	-	-
Ibuprofen + Loratadine fixed dose	Phase 3	Common Cold	-	-
Formoterol/Budesonide	Phase 3	Asthma	-	-
Meloxicam	Phase 3	Dysmenorrhea	-	-
Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)	Phase 3	Cold	-	-
Pregabalin 75mg/ Tramadol 50 mg	Phase 3	Neuropathic Pain	-	-
Formoterol/Fluticasone	Phase 3	Asthma	-	-
Moxifloxacin / Dexamethasone Ophthalmic Solution	Phase 3	Cataract Extraction	-	-
Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen (Dactylis Glomerata)	-	-
DP/MG/14-1	Phase 2	Rhinitis	-	-
AS012	Phase 2	Non-segmental Vitiligo	-	-
1 (Dose Response Skin Prick Tests)	Phase 2	Cat Allergy (Disorder)	-	-
Prick test Chenopodium album allergen extract	Phase 2	Allergy to Chenopodium Album	-	-
Immunotherapy with modified extract of P. pratense pollen	Phase 2	Rhinitis, Allergic, Seasonal	-	-
Grass pollen allergenic extract (L. perenne-C. dactylon )	Phase 2	Allergic Rhinoconjunctivitis	-	-
Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)	Phase 2	Allergy	-	-
Cupressus arizonica	Phase 2	Allergy to Tree Pollen	-	-
Prick test Platanus acerifolia allergen extract	Phase 2	Allergy to Platanus Acerifolia	-	-
Four different concentrations of Secale cereale allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen (Secale Cereale)	-	-
COVID-19 vaccine HIPRA 10	Phase 2	Covid19	-	-
Evogliptin	Phase 2	Diabetes Mellitus, Type 2	-	-
Four different concentrations of Poa pratensis allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen	-	-
Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control	Phase 2	Allergy to Mites	-	-
Sodium Hyaluronate Ophthalmic 0.4% BID	Phase 2	Dry Eye	-	-
four differente concentrations of Alternaria alternata allergen extract, positive control and negative control	Phase 2	Allergy to Alternaria Fungus	-	-
Artemisia vulgaris	Phase 2	Allergy to Pollen	-	-
etoricoxib-tramadol	Phase 2	Acute Pain	-	-
PRO-157	Phase 2	Bacterial Conjunctivitis	-	-
Lolium allergen extract	Phase 2	Allergy to Grass Pollen	-	-
Prick test Dermatophagoides pteronyssinus allergen extract	Phase 2	Allergy Dermatophagoides Pteronyssinus	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Laboratorios Farmaceuticos Rovi, S.A./ADR

Market Overview

LRVIY News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals